Clinical Trial Update: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. [Phase 3]

View source ↗

Summary

An open-label Phase 3 trial comparing Lutetium-177Lu vipivotide tetraxetan to observation in PSMA-positive oligometastatic prostate cancer is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligometastatic Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Oligometastatic Prostate Cancer (OMPC) | Phase 3 | Status: RECRUITING